| Literature DB >> 27799823 |
Janet H Southerland1, Danielle G Gill1, Pandu R Gangula2, Leslie R Halpern1, Cesar Y Cardona3, Charles P Mouton4.
Abstract
Hypertension is a chronic illness affecting more than a billion people worldwide. The high prevalence of the disease among the American population is concerning and must be considered when treating dental patients. Its lack of symptoms until more serious problems occur makes the disease deadly. Dental practitioners can often be on the frontlines of prevention of hypertension by evaluating preoperative blood pressure readings, performing risk assessments, and knowing when to consider medical consultation of a hypertensive patient in a dental setting. In addition, routine follow-up appointments and patients seen on an emergent basis, who may otherwise not be seen routinely, allow the oral health provider an opportunity to diagnose and refer for any unknown disease. It is imperative to understand the risk factors that may predispose patients to hypertension and to be able to educate them about their condition. Most importantly, the oral health care provider is in a pivotal position to play an active role in the management of patients presenting with a history of hypertension because many antihypertensive agents interact with pharmacologic agents used in the dental practice. The purpose of this review is to provide strategies for managing and preventing complications when treating the patient with hypertension who presents to the dental office.Entities:
Keywords: blood pressure medicines; dental; guidelines; high blood pressure; inflammation; metabolic disease
Year: 2016 PMID: 27799823 PMCID: PMC5074706 DOI: 10.2147/CCIDE.S99446
Source DB: PubMed Journal: Clin Cosmet Investig Dent ISSN: 1179-1357
Classification of hypertension according to the JNC6 and JNC714,17
| Stages of hypertension | Range for systolic and diastolic blood pressure |
|---|---|
| Normal blood pressure | Systolic <120 mmHg and diastolic <80 mmHg |
| Prehypertension | Systolic 120–139 mmHg or diastolic 80–89 mmHg |
| Stage 1 hypertension | Systolic 140–159 mmHg or diastolic 90–99 mmHg |
| Stage 2 hypertension | Systolic ≥160 mmHg or diastolic ≥100 mmHg |
| Hypertensive urgency | Severe hypertension (diastolic pressure usually >120 mmHg); no end-organ damage |
| Hypertensive emergency | Severe hypertension (diastolic pressure usually >120 mmHg); end-organ damage |
| “White coat” hypertension | Elevated blood pressure secondary to fear and anxiety from a health care provider |
Abbreviations: JNC6, 6th joint national committee report; JNC7, 7th joint national committee report.
Risk factors for primary hypertension according to the JNC617
| Risk factors |
|---|
| Age |
| Contraceptive use/menopause |
| Obesity |
| Family history |
| Race |
| Reduced nephron number |
| Diabetes |
| Dyslipidemia |
| High-sodium diet |
| Excessive alcohol consumption |
| Physical inactivity |
| Fetal origins of adult disease |
| Personality traits/depression |
| Hypovitaminosis D |
| Low education |
| Socioeconomic status |
| Tobacco use |
| Stress |
Notes: Data from National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda: National High Blood Pressure Education Program; 2004.
Abbreviation: JNC6, 6th joint national committee report.
Factors that interfere with control of blood pressure
| Nonsteroidal anti-inflammatory agents |
| Aspirin |
| Selective COX-2 inhibitors |
| Sympathomimetic agents (decongestants, diet pills, cocaine) |
| Stimulants (methylphenidate, dexmethylphenidate, dextroamphetamine, amphetamine, methamphetamine, modafinil, ephedrine) |
| Alcohol |
| Oral contraceptives |
| Cyclosporine |
| Erythropoietin |
| Natural licorice |
| Grapefruit/orange juice |
| Acetaminophen |
| Antidepressants (bupropion, tricyclic antidepressants, selective serotonin reuptake inhibitors, venlafaxine, monoamine oxidase inhibitors) |
| Corticosteroids |
| Dietary and herbal supplements (eg, ginseng, ephedra, ma huang, bitter orange) |
| Tacrolimus |
Abbreviation: COX, cyclooxygenase.
Common antihypertensive drug classes, dental side effects, and drug–drug interactions
| Drug Class | Dental Side Effects | Common Drug Interactions |
|---|---|---|
| Beta-blockers | Dry mouth, | NSAIDs, |
| ACE inhibitors | Rash, | NSAIDs |
| Angiotensin II receptor blockers | Dry mouth, | Systemic antifungals, |
| Calcium channel blockers | Gingival enlargement, | Benzodiazepines, |
| Alpha-blockers | Dry mouth, | NSAIDs, |
| Diuretics | Dry mouth, | NSAIDs, |
| Direct-acting vasodilators | Facial flushing, | NSAIDS, |
| Central-acting agents | Dry mouth, | NSAIDS, |
| Combined alpha/beta blockers | Taste changes | Epinephrine, |
Common antihypertensive dental side effects8,9
| Drug class | Dental side effects |
|---|---|
| Beta-blockers | Dry mouth, taste changes, lichenoid reaction |
| ACE inhibitors | Dry cough, loss of taste, dry mouth, ulceration, angioedema |
| Angiotensin II receptor blockers | Dry mouth, angioedema, sinusitis, taste loss |
| Calcium channel blockers | Gingival enlargement, dry mouth, altered taste |
| Alpha-blockers | Dry mouth |
| Alpha-2 agonists, central-acting | Dry mouth, taste changes, parotid pain |
| Diuretics | Dry mouth, lichenoid reaction, orthostatic hypotension |
| Vasodilators | Facial flushing, possible increased risk of gingival bleeding, and infection |
| Renin inhibitors | Angioedema, rash, cough, tinnitus, parosmia |
| Peripheral dopamine-1 receptor agonist | Leukocytosis, bleeding |
| Peripheral adrenergic inhibitors | Dry mouth, swelling, nosebleeds |
Abbreviation: ACE, angiotensin-converting enzyme.
Hypertensive emergency drugs8,10,14,31
| Drug | Drug class | Dosage |
|---|---|---|
| Fenoldopam | Peripheral dopamine-1 receptor agonist | 0.1 μg/kg/min as IV infusion |
| Hydralazine | Vasodilator | 10–20 mg IV |
| Nicardipine | Calcium channel blocker (dihydropyridine) | 5–15 mg/h IV infusion |
| Nitroglycerin | Vasodilators | 5–100 μg/min IV infusion |
| Esmolol | Beta-blocker (beta-1 cardioselective) | 80–500 μg/kg loading dose over 1 minute; then initiate IV infusion at 25–300 μg/kg/min |
| Labetalol | Combined alpha/beta-blocker | 2 mg/min, up to 300 mg; or 20 mg over 2 minutes, then 40–80 mg at 10-minute intervals up to 300 mg total 0.5–2 mg/min as IV infusion following an initial 20 mg IV bolus |
| Metoprolol | Beta-blocker (beta-1 cardioselective) | Initial 1.25–5 mg IV, followed by 2.5–15 mg IV every 3–6 hours |
| Phentolamine | Alpha-blocker (nonselective) | 5–15 mg IV bolus every 5–15 minutes |
| Clonidine | Alpha-2 agonists, central-acting | 200 mg po, followed by 200 mg every hour until desired effect |
| Captopril | ACE inhibitor | 25 mg po |
Abbreviations: IV, intravenous; IM, intramuscular; h, hour; ACE, angiotensin-converting enzyme; po, per os (oral administration).
ASA PS classification system43–45
| ASA PS 1 | Normal healthy patient |
|---|---|
| ASA PS 2 | Patients with mild systemic disease |
| ASA PS 3 | Patients with severe systemic disease |
| ASA PS 4 | Patients with severe systemic disease that is a constant threat to life |
| ASA PS 5 | Moribund patients who are not expected to survive without the operation |
| ASA PS 6 | A declared brain-dead patient whose organs are being removed for donor purposes |
| E | The addition of “E” denotes emergency surgery: an emergency is defined as existing when delay in treatment of the patient would lead to a significant increase in the threat to life or body part |
Abbreviations: ASA, American Society of Anesthesiologists; PS, physical status; E, emergency.
Estimated energy requirement for various activities37,44
| Estimated energy | Activity |
|---|---|
| 1 MET | Self-care |
| 4 METs | Light housework (eg, dusting, washing dishes) |
| >10 METs | Strenuous sports (eg, swimming, singles tennis, football, basketball, skiing) |
Abbreviations: MET, metabolic equivalent; h, hour.